Skip to main content
. 2022 Mar 30;22(5):535–544. doi: 10.1007/s40256-022-00525-w

Table 3.

Clinical characteristics and outcomes in responders vs. nonresponders at 24-month follow-up

Variables Echocardiographic responder Echocardiographic nonresponder p valuea Functional responder Functional nonresponder p valuea
Demographics
 Age, years 64.5 (33; 88) 67.5 (33; 88) 0.43 65 (35; 85) 66 (33; 88) 0.66
 Male 89/116 (76.7) 52/58 (89.7) 0.04 76/97 (78.4) 80/97 (82.5) 0.47
 BMI 28.98 ± 5.56 29.68 ± 5.52 0.44 29.43 ± 5.62 28.41 ± 6.27 1.00
Medical history
 DCMP 66/116 (56.9) 24/58 (41.4) 0.05 56/97 (57.7) 42/97 (43.3) 0.04
 ICMP 50/116 (43.1) 37/58 (63.8) 0.01 44/97 (45.4) 56/97 (57.7) 0.09
Laboratory values
 NT-proBNP pg/ml 452 (13; 4203) 1097 (159; 4571) 0.003 544.5 (13; 4571) 457 (152; 4331) 0.75
NYHA classification
 III 19/69 (27.5) 13/35 (37.1) 0.08 10/64 (15.6) 25/44 (56.8) <0.001
 IV 1/69 (1.4) 2/35 (5.7) 0.08 0/64 (0.0) 3/44 (6.8) <0.001
Echocardiographic values
 LVEF, % 38 (15; 64) 22.5 (13; 55) < 0.001 33 (15; 60) 37 (13; 64) 0.11
 TAPSE, mm 19.5 (2.5; 31) 17 (11; 27) 0.01 19 (11; 31) 18 (2.5; 31) 0.34
Clinical outcomes
 Mortality 6/116 (5.2) 7/58 (12.1) 0.1 3/97 (3.1) 11/97 (11.3) 0.01
 Congestion 5/70 (4.3) 7/35 (20.0) 0.05 6/65 (9.2) 5/45 (11.1) 0.75
 Hospitalization 40/74 (54.1) 21/38 (55.3) 0.97 38/67 (56.7) 23/52 (44.2) 0.18

Data are presented as n (%), median (minimum; maximum), or mean ± standard deviation unless otherwise indicated

Bold text indicates a statistically significant difference with a p-value less than 0.05

BMI body mass index, DCMP dilated cardiomyopathy, ICMP ischemic cardiomyopathy, LVEF left ventricular ejection fraction, NT-proBNP N-terminal pro-B-type natriuretic peptide, NYHA New York Heart Association, TAPSE tricuspid annular plane systolic excursion

ap values for the comparison between responders and nonresponders